KALA PHARMACEUTICALS INC's ticker is KALA and the CUSIP is 483119103. A total of 123 filers reported holding KALA PHARMACEUTICALS INC in Q3 2020. The put-call ratio across all filers is 3.55 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q1 2021 | $5,304,000 | -0.6% | 786,883 | 0.0% | 0.19% | -21.8% |
| Q4 2020 | $5,335,000 | -9.6% | 786,883 | 0.0% | 0.24% | -30.2% |
| Q3 2020 | $5,902,000 | -28.6% | 786,883 | 0.0% | 0.34% | -42.5% |
| Q2 2020 | $8,270,000 | +19.6% | 786,883 | 0.0% | 0.59% | -5.4% |
| Q1 2020 | $6,917,000 | +4.0% | 786,883 | -24.6% | 0.63% | +0.5% |
| Q2 2019 | $6,654,000 | -22.9% | 1,043,020 | 0.0% | 0.62% | -27.4% |
| Q1 2019 | $8,626,000 | +69.1% | 1,043,020 | 0.0% | 0.86% | +32.1% |
| Q4 2018 | $5,100,000 | -50.5% | 1,043,020 | 0.0% | 0.65% | -37.3% |
| Q3 2018 | $10,295,000 | -28.1% | 1,043,020 | 0.0% | 1.04% | -43.7% |
| Q2 2018 | $14,321,000 | -13.3% | 1,043,020 | 0.0% | 1.84% | -21.1% |
| Q1 2018 | $16,511,000 | -22.9% | 1,043,020 | -10.0% | 2.34% | -49.0% |
| Q4 2017 | $21,428,000 | -19.0% | 1,158,911 | 0.0% | 4.59% | -14.2% |
| Q3 2017 | $26,470,000 | – | 1,158,911 | – | 5.35% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Athyrium Capital Management, LP | 1,333,333 | $5,073,000 | 100.00% |
| CAXTON CORP | 1,483,343 | $5,644,000 | 6.36% |
| Polaris Venture Management Co. V, L.L.C. | 1,197,032 | $4,555,000 | 2.59% |
| RA Capital Management | 4,537,478 | $17,265,000 | 1.03% |
| Orbimed Advisors | 3,447,840 | $13,119,000 | 0.25% |
| Matisse Capital | 46,500 | $177,000 | 0.22% |
| PURA VIDA INVESTMENTS, LLC | 332,831 | $1,266,000 | 0.22% |
| Sofinnova Investments, Inc. | 478,206 | $1,819,000 | 0.16% |
| HARBOURVEST PARTNERS LLC | 99,186 | $377,000 | 0.16% |
| ALGERT GLOBAL LLC | 47,195 | $180,000 | 0.07% |